Intellectus Partners LLC Buys Shares of 61,036 Hims & Hers Health, Inc. $HIMS

Intellectus Partners LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 61,036 shares of the company’s stock, valued at approximately $3,043,000.

A number of other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC raised its holdings in shares of Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after buying an additional 227 shares during the period. Bessemer Group Inc. grew its position in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares in the last quarter. True Vision MN LLC increased its stake in Hims & Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock worth $467,000 after purchasing an additional 328 shares during the period. Allworth Financial LP increased its stake in Hims & Hers Health by 20.0% during the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock worth $56,000 after purchasing an additional 334 shares during the period. Finally, Signaturefd LLC lifted its position in shares of Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Truist Financial dropped their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Weiss Ratings restated a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday, October 14th. KeyCorp started coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating on the stock. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and an average target price of $38.92.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 11,592 shares of the company’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $57.13, for a total transaction of $662,250.96. Following the completion of the transaction, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at approximately $4,012,354.16. This represents a 14.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 900 shares of the stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $58.25, for a total value of $52,425.00. Following the completion of the transaction, the insider owned 291,439 shares in the company, valued at approximately $16,976,321.75. The trade was a 0.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,432,271 shares of company stock valued at $74,229,585 in the last ninety days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS opened at $45.55 on Monday. Hims & Hers Health, Inc. has a twelve month low of $18.33 and a twelve month high of $72.98. The firm’s fifty day simple moving average is $51.39 and its 200-day simple moving average is $50.61. The firm has a market capitalization of $10.30 billion, a price-to-earnings ratio of 56.94, a PEG ratio of 3.15 and a beta of 2.20. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business’s revenue for the quarter was up 72.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.06 EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.